Showing 111-120 of 6901 results for "".
How Do You Approach Obesity During an Office Visit?
https://reachmd.com/programs/everyday-family-medicine/how-do-you-approach-obesity-during-office-visit/7432/Approaching the topic of body weight with patients is a sensitive issue. It can be challenging for providers to discuss health issues related to excess weight while also remaining sensitive to terminology and language that may offend patients. Host Dr. Jennifer Caudle welcomes Dr. Adarsh Gupta to prE-Visits Show Comparable Acne Management Outcomes to In-Person Care
https://reachmd.com/programs/clinicians-roundtable/e-visits-vs-in-person-acne-care-outcomes/49087/Remnant Cholesterol: The Missing Link in ASCVD risk
https://reachmd.com/programs/cme/remnant-cholesterol-the-missing-link-in-ascvd-risk/33226/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Targeting Mixed Hyperlipidemia with APOC3 Inhibition
https://reachmd.com/programs/cme/targeting-mixed-hyperlipidemia-with-apoc3-inhibition/33227/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.SHTG: Defining the Unmet Clinical Need
https://reachmd.com/programs/cme/shtg-defining-the-unmet-clinical-need/33224/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Setting the Bar: Guideline-Recommended Treatment in Hypertriglyceridemia
https://reachmd.com/programs/cme/setting-the-bar-guideline-recommended-treatment-in-hypertriglyceridemia/33221/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.SHTG: Decoding the Latest Clinical Trial Outcomes
https://reachmd.com/programs/cme/shtg-decoding-the-latest-clinical-trial-outcomes/33225/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.APOC3 Inhibition: A Novel Approach to Lowering TGs
https://reachmd.com/programs/cme/apoc3-inhibition-a-novel-approach-to-lowering-tgs/33222/Listen to experts discussing the latest developments in APOC3 inhibition for the treatment of patients with FCS, SHTG, and mixed hyperlipidemia.Female Sexual Dysfunction: Updates from Omnia Education's Women's Health Annual Visit (WHAV)
https://reachmd.com/programs/clinicians-roundtable/female-sexual-dysfunction-updates-from-omnia-educations-womens-health-annual-visit-whav/6843/Featured from the Omnia Education live activity entitled "Women's Health Annual Visit" (WHAV) are Dr. Andrea Singer, Associate Professor of Medicine and Obsetrics and Gynecology at Georgetown University Medical Center, and Dr. Susan Kellogg-Spadt, Professor of Obstetrics and Gynecology at Drexler UnInterventional COPD Care Reduces Healthcare Visits and Improves Outcomes
https://reachmd.com/programs/clinicians-roundtable/interventional-copd-care-reduces-healthcare-visits-and-improves-outcomes/24555/Explore a study that evaluated a unique approach to detecting and treating patients with undiagnosed COPD or asthma.